Status:
RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT and KarXT + KarX-EC in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Lead Sponsor:
Karuna Therapeutics
Conditions:
Psychosis Associated With Alzheimer's Disease
Eligibility:
All Genders
55-90 years
Phase:
PHASE3
Brief Summary
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027, CN012-0056 or CN012-0034. Subjects (randomized or non-ra...
Eligibility Criteria
Inclusion
- Must have completed study CN012-0026, CN012-0027, CN012-0034 or CN012-0056.
- Subject was aged 55 to 90 years, inclusive, at the time of enrollment into the parent CN012-0026, CN012-0027, CN012-0034 or CN012-0056 study.
- Can understand the nature of the study and protocol requirements and provide a signed informed consent or, if deemed not competent to provide informed consent, the subject's legally acceptable representative must provide informed consent, and the subject must provide informed assent before any study assessments are performed.
- At entry into this study, or any time during the study, if a subject needs to relocate from home or residential assisted-living facility to a nursing home facility, the Sponsor/Medical Monitor must approve the subject's participation in the study.
- Have an identified or proxy caregiver (spends approximately 10 hours/week with the subject).
Exclusion
- Significant or severe medical conditions that, in the opinion of the Investigator, could jeopardize the safety of the subject, ability to complete or comply with the study procedures or validity of the study results.
- Clinically significant abnormalities, including any finding(s) from the ECG, laboratory tests, physical examination, or vital signs, at the EOT visit of Study CN012-0026, CN012-0027, CN012-0034 or CN012-0056 that the Investigator, in consultation with the Medical Monitor, are considered to jeopardize the safety of the subject.
- Subjects participating in another investigational drug or device study or planning on participating in another clinical study during the duration of CN012-0028.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Key Trial Info
Start Date :
July 11 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 7 2027
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT05980949
Start Date
July 11 2023
End Date
September 7 2027
Last Update
January 5 2026
Active Locations (411)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 1029
Homewood, Alabama, United States, 35209-6809
2
Local Institution - 1-13H98LK9
Chandler, Arizona, United States, 85224-6231
3
Local Institution - 1227
Chandler, Arizona, United States, 85224
4
Local Institution - 1116
Chandler, Arizona, United States, 85286